Addendum

Relugolix/estradiol/norethisterone (uterine fibroids) - Addendum to Commission A21-112

Report documents

Indication:

Adult women of reproductive age with moderate to severe symptoms of uterine fibroids

Result of dossier assessment:

Unchanged after addendum:

Women for whom watchful waiting is the best individual choice: hint of considerable added benefit
Women for whom symptom-oriented treatment (with gestagens or ulipristal acetate) or an invasive treatment option is the best individual choice: added benefit not proven

Federal Joint Committee (G-BA)

2022-02-18 A G-BA decision was published.

Project no.: A22-01
Commission: Commission awarded on 11.01.2022 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Digestion, metabolism and hormones
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.